These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 23179373

  • 1. A UK analysis of the cost-effectiveness of Humalog Mix75/25 and Mix50/50 versus long-acting basal insulin.
    Pollock RF, Curtis BH, Smith-Palmer J, Valentine WJ.
    Adv Ther; 2012 Dec; 29(12):1051-66. PubMed ID: 23179373
    [Abstract] [Full Text] [Related]

  • 2. A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States.
    Pollock RF, Curtis BH, Valentine WJ.
    J Med Econ; 2012 Dec; 15(4):766-75. PubMed ID: 22413830
    [Abstract] [Full Text] [Related]

  • 3. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
    Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, McKendrick J, Tucker DM, Foos V, Palmer AJ.
    Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
    [Abstract] [Full Text] [Related]

  • 4. Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting.
    Valentine WJ, Palmer AJ, Lammert M, Nicklasson L, Foos V, Roze S.
    Curr Med Res Opin; 2005 Dec; 21(12):2063-71. PubMed ID: 16368057
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials.
    Palmer AJ, Roze S, Valentine WJ, Smith I, Wittrup-Jensen KU.
    Curr Med Res Opin; 2004 Nov; 20(11):1729-46. PubMed ID: 15537473
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea.
    Lee KH, Seo SJ, Smith-Palmer J, Palmer JL, White J, Valentine WJ.
    Value Health; 2009 Nov; 12 Suppl 3():S55-61. PubMed ID: 20586983
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective.
    Evans M, Wolden M, Gundgaard J, Chubb B, Christensen T.
    Diabetes Obes Metab; 2014 Apr; 16(4):366-75. PubMed ID: 24373113
    [Abstract] [Full Text] [Related]

  • 8. Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US.
    Bruhn D, Martin AA, Tavares R, Hunt B, Pollock RF.
    J Med Econ; 2016 Jul; 19(7):672-83. PubMed ID: 26882484
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of switching patients with type 2 diabetes from insulin glargine to insulin detemir in Chinese setting: a health economic model based on the PREDICTIVE study.
    Yang L, Christensen T, Sun F, Chang J.
    Value Health; 2012 Jul; 15(1 Suppl):S56-9. PubMed ID: 22265068
    [Abstract] [Full Text] [Related]

  • 12. Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16).
    Pollock RF, Valentine WJ, Marso SP, Andersen A, Gundgaard J, Hallén N, Tutkunkardas D, Magnuson EA, Buse JB, DEVOTE study group.
    Appl Health Econ Health Policy; 2019 Oct; 17(5):615-627. PubMed ID: 31264138
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Is the current standard of care leading to cost-effective outcomes for patients with type 2 diabetes requiring insulin? A long-term health economic analysis for the UK.
    Valentine WJ, Curtis BH, Pollock RF, Van Brunt K, Paczkowski R, Brändle M, Boye KS, Kendall DM.
    Diabetes Res Clin Pract; 2015 Jul; 109(1):95-103. PubMed ID: 25989713
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.